ABSTRACT
Objectives To evaluate SARS-CoV-2 surface and air contamination during the peak of the COVID-19 pandemic in London.
Design Prospective cross-sectional observational study.
Setting An acute NHS healthcare provider.
Participants All inpatient wards were fully occupied by patients with COVID-19 at the time of sampling.
Interventions Air and surface samples were collected from a range of clinical areas and a public area of the hospital. An active air sampler was used to collect three or four 1.0 m3 air samples in each area. Surface samples were collected by swabbing approximately 25 cm2 of items in the immediate vicinity of each air sample. SARS-CoV-2 was detected by RT-qPCR and viral culture using Vero E6 and Caco2 cells; additionally the limit of detection for culturing SARS-CoV-2 dried onto surfaces was determined.
Main outcome measures SARS-CoV-2 detected by PCR or culture.
Results Viral RNA was detected on 114/218 (52.3%) of surface and 14/31 (38.7%) air samples but no virus was cultured. The proportion of surface samples contaminated with viral RNA varied by item sampled and by clinical area. Viral RNA was detected on surfaces and in air in public areas of the hospital but was more likely to be found in areas immediately occupied by COVID-19 patients (67/105 (63.8%) in areas immediately occupied by COVID-19 patients vs. 29/64 (45.3%) in other areas (odds ratio 0.5, 95% confidence interval 0.2-0.9, p=0.025, Fisher’s exact test). The PCR Ct value for all surface and air samples (>30) indicated a viral load that would not be culturable.
Conclusions Our findings of extensive viral RNA contamination of surfaces and air across a range of acute healthcare settings in the absence of cultured virus underlines the potential risk from surface and air contamination in managing COVID-19, and the need for effective use of PPE, social distancing, and hand/surface hygiene.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: JAO reports personal fees from Gama Healthcare Ltd and Pfizer in the past three years outside the submitted work; Dr. Kinross reports grants from H2020 (ITN grant), NIHR (i4i grant), CRUK fellowship, personal fees from Verb robotics / Ethicon and Medtronic, and other relationships with Cerulean Health, One Welbeck day surgery, and LNC therapeutics; all other authors report no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, all other authors report no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Infections in partnership with Public Health England (PHE), in collaboration with, Imperial Healthcare Partners, University of Cambridge and University of Warwick supported this work. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health and Social Care or Public Health England. Professor Alison Holmes is a National Institute for Health Research (NIHR) Senior Investigator. International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) provided funding for JZ and laboratory materials used for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The work was registered locally as an NHS service evaluation.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data related to this work will be shared upon request.
